Lexeo Therapeutics GAAP EPS of -$0.89 misses by $0.24 [Seeking Alpha]
Lexeo Therapeutics, Inc. (LXEO)
Company Research
Source: Seeking Alpha
As of September 30, 2024, cash and cash equivalents were $157.0 million, which Lexeo believes will be sufficient to fund operations into 2027. More on Lexeo Therapeutics Seeking Alpha's Quant Rating on Lexeo Therapeutics Historical earnings data for Lexeo Therapeutics Financial information for Lexeo Therapeutics Recommended For You More Trending News
Show less
Read more
Impact Snapshot
Event Time:
LXEO
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
LXEO alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
LXEO alerts
High impacting Lexeo Therapeutics, Inc. news events
Weekly update
A roundup of the hottest topics
LXEO
News
- Lexeo Therapeutics Appoints Kyle Rasbach as Chief Financial Officer [Yahoo! Finance]Yahoo! Finance
- Lexeo Therapeutics Appoints Kyle Rasbach as Chief Financial OfficerGlobeNewswire
- Paula H. Cholmondeley Bought 96% More Shares In Lexeo Therapeutics [Yahoo! Finance]Yahoo! Finance
- How decentralisation can fill the gaps in Alzheimer's research [Yahoo! Finance]Yahoo! Finance
- Lexeo Therapeutics, Inc. (NASDAQ: LXEO) had its price target raised by analysts at HC Wainwright from $21.00 to $23.00. They now have a "buy" rating on the stock.MarketBeat
LXEO
Sec Filings
- 12/20/24 - Form EFFECT
- 12/19/24 - Form 8-K
- 12/13/24 - Form S-3
- LXEO's page on the SEC website